Indications for TYGACIL:
Susceptible complicated skin and skin structure and intra-abdominal infections. Community-acquired bacterial pneumonia (CABP).
Limitations of Use:
Not for treating diabetic foot infection, hospital-acquired or ventilator-associated pneumonia.
≥18yrs: Give by IV infusion over 30–60 mins. 100mg once, then 50mg every 12hrs. Skin, skin structure, and intra-abdominal infections: treat for 5–14 days. CABP: treat for 7–14 days. Severe hepatic impairment (Child Pugh C): 100mg once, then 25mg every 12hrs.
<18yrs: not recommended. See full labeling for suggested dosages when no alternative antibacterial drugs are available.
Risk of increase in all-cause mortality; reserve for use when alternatives are not suitable. Monitor for hepatic dysfunction and pancreatitis; consider discontinuing if occurs. Ventilator-associated pneumonia. Complicated intra-abdominal infections secondary to intestinal perforation: avoid monotherapy (sepsis/septic shock may develop). Severe hepatic impairment. Risk of tooth discoloration, enamel hypoplasia, and reversible bone growth inhibition (during 2nd/3rd trimester of pregnancy, infancy, and childhood up to age 8yrs). Pregnancy (2nd/3rd trimester). Nursing mothers (avoid if therapy >3 weeks): may consider interrupting breastfeeding and pumping and discarding breastmilk during and for 9 days after the last dose.
Monitor warfarin. May antagonize oral contraceptives.
Nausea, vomiting, diarrhea, abdominal pain, headache, increased SGPT; pancreatitis, anaphylaxis, C. difficile-associated diarrhea.
Single-use vials (5mL, 10mL)—10